Publication | Open Access

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Inbuild TrialParallel-group TrialAdvanced Lung DiseasePulmonary FibrosisPulmonary MedicineMedicinePulmonary DiseaseRadiology